Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
HYCOFENIX
Overview
What is HYCOFENIX?
HYCOFENIX (hydrocodone bitartrate, pseudoephedrine hydrochloride,
and guaifenesin) oral solution contains hydrocodone bitartrate (a
centrally-acting opioid antitussive), pseudoephedrine hydrochloride
(an indirect sympathomimetic amine), and guaifenesin (an expectorant).
Each 5 mL dose of HYCOFENIX contains: hydrocodone bitartrate, USP,
2.5 mg; pseudoephedrine hydrochloride, USP, 30 mg; and guaifenesin,
USP, 200 mg.
HYCOFENIX
also contains: black raspberry flavor, citric acid, D&C Red #33,
FD&C Blue #1, glycerin, methylparaben, polyethylene glycol, propylparaben,
purified water, saccharin sodium, sodium citrate, and sorbitol.
Hydrocodone Bitartrate
Pseudoephedrine Hydrochloride
Guaifenesin
What does HYCOFENIX look like?




What are the available doses of HYCOFENIX?
Oral solution: Each 5 mL contains
hydrocodone bitartrate, USP, 2.5 mg; pseudoephedrine hydrochloride,
USP, 30 mg; and guaifenesin, USP, 200 mg. ()
What should I talk to my health care provider before I take HYCOFENIX?
How should I use HYCOFENIX?
HYCOFENIX is indicated for symptomatic relief
of cough, nasal congestion, and to loosen mucus associated with the
common cold.
Important Limitations of Use:
see Pediatric Use ()
Adults and adolescents 18 years of age and older: 10 mL
every 4 to 6 hours, not to exceed 4 doses (40 mL) in 24 hours ()
Measure HYCOFENIX with an accurate milliliter measuring
device. ()
What interacts with HYCOFENIX?
Sorry No Records found
What are the warnings of HYCOFENIX?
Sorry No Records found
What are the precautions of HYCOFENIX?
Sorry No Records found
What are the side effects of HYCOFENIX?
Sorry No records found
What should I look out for while using HYCOFENIX?
HYCOFENIX is contraindicated
in:
p806216881476151971
Concomitant use of opioids with benzodiazepines
or other central nervous system (CNS) depressants, including alcohol,
may result in profound sedation, respiratory depression, coma, and
death []. Avoid use of opioid cough medications in patients taking
benzodiazepines, other CNS depressants, or alcohol.
What might happen if I take too much HYCOFENIX?
No human overdosage data are
available for HYCOFENIX.
Hydrocodone
Overdosage with hydrocodone is characterized
by respiratory depression (a decrease in respiratory rate and/or tidal
volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing
to stupor or coma, skeletal muscle flaccidity, dizziness, ringing
in the ears, confusion, blurred vision, eye problems, cold and clammy
skin, and sometimes bradycardia and hypotension. In severe overdose,
apnea, circulatory collapse, cardiac arrest and death may occur.
Pseudoephedrine
Overdosage with
sympathomimetics such as pseudoephedrine may give rise to giddiness,
headache, nausea, vomiting, sweating, thirst, tachycardia, precordial
pain, palpitations, difficulty in micturition, muscle weakness and
tenseness, anxiety, restlessness, and insomnia. Many patients can
present a toxic psychosis with delusion and hallucinations. Some may
develop cardiac arrhythmias, circulatory collapse, convulsion, coma,
and respiratory failure.
Guaifenesin
Overdosage with guaifenesin can cause depression
of the central nervous system. While present in polypharmacy overdoses,
one case of overdose with only significant levels of guaifenesin has
been reported. Symptoms included slurred speech, shallow respirations,
reduced heart rate with rhythm sinus bradycardia, followed by asystole.
Treatment of overdosage consists
of discontinuation of HYCOFENIX together with institution of appropriate
therapy. Primary attention should be given to the reestablishment
of adequate respiratory exchange through provision of a patent airway
and the institution of assisted or controlled ventilation. The opioid
antagonist naloxone hydrochloride is a specific antidote for respiratory
depression which may result from overdosage or unusual sensitivity
to opioids including hydrocodone. Therefore, an appropriate dose of
naloxone hydrochloride should be administered, preferably by the intravenous
route, simultaneously with efforts at respiratory resuscitation. For
further information, see full prescribing information for naloxone
hydrochloride. An antagonist should not be administered in the absence
of clinically significant respiratory depression. Oxygen, intravenous
fluids, vasopressors, and other supportive measures should be employed
as indicated. Gastric emptying may be useful in removing unabsorbed
drug.
How should I store and handle HYCOFENIX?
HYCOFENIX (hydrocodone bitartrate, pseudoephedrine hydrochloride, and guaifenesin) oral solution is supplied as a violet-colored, black raspberry flavored liquid containing 2.5 mg hydrocodone bitartrate, 30 mg pseudoephedrine hydrochloride, and 200 mg guaifenesin in each 5 mL. It is available in: White HDPE bottles of 16 fl. oz. (473 mL): 0178-3291-16 White HDPE bottles of 4 fl. oz. (118 mL): 0178-3291-04 Store solution at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Dispense in a tight, light-resistant container, as defined in the USP, with a childresistant closure.
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Hydrocodone is a semisynthetic narcotic
antitussive and analgesic with multiple actions qualitatively similar
to those of codeine. The precise mechanism of action of hydrocodone
and other opiates is not known; however, hydrocodone is believed to
act directly on the cough center. In excessive doses, hydrocodone
will depress respiration. Hydrocodone can produce miosis, euphoria,
and physical and physiological dependence.
Pseudoephedrine hydrochloride is an orally
active sympathomimetic amine and exerts a decongestant action on the
nasal mucosa. Pseudoephedrine hydrochloride is recognized as an effective
agent for the relief of nasal congestion due to upper respiratory
allergies or common cold. Pseudoephedrine produces peripheral effects
similar to those of ephedrine and central effects similar to, but
less intense than, amphetamines. It has the potential for excitatory
side effects.
Guaifenesin is an expectorant
the action of which promotes or facilitates the removal of secretions
from the respiratory tract. The precise mechanism of action of guaifenesin
is not known; however, it is thought to act as an expectorant by increasing
the volume and reducing the viscosity of secretions in the trachea
and bronchi. In turn, this may increase the efficiency of the cough
reflex and facilitate removal of the secretions.
Non-Clinical Toxicology
HYCOFENIX is contraindicated in:p806216881476151971
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death []. Avoid use of opioid cough medications in patients taking benzodiazepines, other CNS depressants, or alcohol.
Concomitant use of opioids, including HYCOFENIX, with benzodiazepines, or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Because of these risks, avoid use of opioid cough medications in patients taking benzodiazepines, other CNS depressants, or alcohol [].
Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. Because of similar pharmacologic properties, it is reasonable to expect similar risk with concomitant use of opioid cough medications and benzodiazepines, other CNS depressants, or alcohol.
Advise both patients and caregivers about the risks of respiratory depression and sedation if HYCOFENIX is used with benzodiazepines, alcohol, or other CNS depressants [].
Use of hydrocodone bitartrate is associated with the following:
Use of pseudoephedrine, a sympathomimetic amine, may result in the following:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The most common adverse reactions experienced by subjects taking a single dose of HYCOFENIX in the clinical setting include the following: Central Nervous System: headache, dizziness, sedation (somnolence); Gastrointestinal System: nausea, diarrhea; Cardiovascular System: decreased blood pressure; Vascular System: hot flush.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).